Biology:Lymphoid enhancer-binding factor 1

Short description: Protein-coding gene in the species Homo sapiens

Generic protein structure example

Lymphoid enhancer-binding factor 1 (LEF1) is a protein that in humans is encoded by the LEF1 gene. It is a member of T cell factor/lymphoid enhancer factor (TCF/LEF) family.

Function

Lymphoid enhancer-binding factor-1 (LEF1) is a 48-kD nuclear protein that is expressed in pre-B and T cells. It binds to a functionally important site in the T-cell receptor-alpha (TCRA) enhancer and confers maximal enhancer activity. LEF1 belongs to a family of regulatory proteins that share homology with high mobility group protein-1 (HMG1). These high mobility groups regulate a vast array of cellular processes through the production of transcription factors, which go on to regulate some of the cells most vital processes, including chromatin remodeling, recombination, DNA replication, DNA repair and transcription. In this shared homology between LEF1 and other members of the HMG family, many of the mechanisms of action that can be seen in the way in which HMG1 interacts with histones, nucleosomes and other chromosomal components can be conferred in how LEF1 regulates many of the same cellular processes, as homology oftentimes helps to infer shared function. In fact, other members of the high mobility group (HMG), including TCF-1, have been shown to possess differential expression at different points within the embryogenesis of murine cells.

Isoforms

The implication of LEF1 short and long isoforms in Transcriptional Regulation

Along with its role in the regulation of the epithelial-mesenchymal transition (EMT) process, LEF1 has also been shown to be implicated in the processes of cellular senescence and aging. Different isoforms have been studied that have differential effects on these biological processes, once again demonstrating the pervasiveness of this family of genes in many different areas of cellular physiology. The biological process is often linked with the senescense-associated secretory phenotype (SASP), wherein aging cells secrete higher levels of immune modulators, pro-inflammatory cytokines, proteases and other biochemicals. These phenotypes that are implicated with SASP's are linked to other age related pathologies, including Chronic obstructive pulmonary disease (COPD) and Idiopathic pulmonary fibrosis (IPF), amongst a host of other comorbidities. While the short LEF1 isoform has been shown to be associated with exacerbation of the effects of cellular senescence, measurement of the activity of transcription factors/regulons associated with the long LEF1 isoform have demonstrated reversal of signs of cellular senescence through a currently unknown mechanism. Research is still being conducted to elucidate the role of these distinct isoforms in contributing to cellular senescence, but the current research has shown the important role LEF1 plays in regulating the transcription of downstream products associated with a wide range of cellular pathways.

Regulation

In terms of the regulation of LEF1 itself, however, a number of enzymes like glycogen synthase kinase 3 (GSK3) and Integrin-linked kinase (ILK) will phosphorylate the β-catenin/(LEF/TCF) complexes, signaling for their activation. As previously mentioned, the signaling of these β-catenin molecules plays a central role in the recruitment and subsequent activation of the LEF/TCF proteins. Working as coregulators of one another, β-catenin and LEF/TCF proteins complex and go on to act downstream of the Wnt signaling pathway, whose ligands are highly expressed in tumors. Recently, some of the upstream molecules present in this Wnt signaling pathway have been elucidated that have connected the missing components. Modern molecular biological techniques helped to identify other upstream regulators of the β-catenin/(LEF/TCF) complex along with GSK3 and ILK, notably casein kinase I ε (CK1-ε). CK1-ε has been shown to be a positive regulator of the β-catenin/(LEF/TCF) complex and even mimics the identity of other proteins in the Wnt signaling pathway, thereby intensifying the effects that LEF and TCF proteins have on the cell.

Clinical significance

LEF1 is highly overexpressed and associated with disease progression and poor prognosis in B-cell chronic lymphocytic leukemia and other kinds of malignancies like colorectal cancer. It is also a promising potential drug target.

Part of the capabilities of the LEF1 family of genes to be implicated in cancer growth is their ability to regulate the epithelial-mesenchymal transition (EMT) process, a cellular pathway by which the inhibition of genes responsible for producing adhesive properties and for polarizing the cell occurs. Though it can be activated independently of β-catenin, much of its effects result from the activation of this protein. When activated by β-catenin, LEF-1 transcription is upregulated and induces the inhibition of the genes which code for polarizing and adhesive properties of the cells. As a result of this LEF/β-catenin-induced inhibition, biochemical transformations take place that allow for heightened migratory and invasive capabilities, increased resistance to apoptosis, and the increased production of components of the extracellular matrix (ECM). Once the LEF1 cells have gained these properties and take on the form of mesenchymal stem cells, they are able to migrate away from their initial sources of attachment and this is when they can begin to exert their cancerous effects.

LEF1 has gained much notability recently for its prevalence in many cancerous pathologies, but even with this increased focus on the mechanisms by which LEF1 and the families of genes it is associated with, many of its downstream effects have not been fully elucidated. As a result, studies are continuing to be published surrounding the LEF1 family of genes, in order to fully expound upon its mechanism of action.

Expression in cancer

Error creating thumbnail:

LEF1 Expression in Human Lung Tissue Lysates

LEF1 is highly overexpressed and associated with disease progression and poor prognosis in B-cell chronic lymphocytic leukemia and other kinds of malignancies like colorectal cancer. It is also a promising potential drug target. Due to its irregular expression common in these forms of cancer, as well as other forms like acute lymphoblastic leukemia (ALL), oral squamous cell carcinoma (OSCC) and even renal cell carcinomas (RCC), LEF1 has been heavily targeted as a drug candidate in a number of different studies. Many of these studies have proven effective in diminishing the growth, migration and invasion rates of tumorigenic cancer cells.

Drug inhibition

The investigation of the role of LEF1 in regards to aging is of extreme importance, as more effective and longevity based therapeutic interventions could be developed that target LEF1 and associated genes, in order to provide a means of minimizing the effects of age-related pathologies and increasing life span for those who are already at higher risk for other age-related comorbidities. The dysregulation of LEF1 has been shown to be highly correlated with the β-catenin binding domain, leading many researchers to consider the downstream effects of knocking out this binding domain and investigating the subsequent effects. The research has revealed that knocking out this domain downregulates the expression the protein products of the LEF1 gene, and as a result, curtailing many of the deleterious effects rapid LEF1 proliferation and migration can have.

In fact, LEF1 silencing in cases of colorectal cancer has been demonstrated to increase the sensitivity of colorectal cancer cells to a number of Platinum-based drugs, including oxaliplatin, 5-FU and irinotecan. These Pt-based drugs act by inhibiting the synthesis of DNA molecules and covalently modifying molecules by forming DNA adducts. In turn, these drugs are able to promote apoptosis in the cancerous cells. Different isoforms of the LEF1 gene, including the long-form and the short-isoform/truncated dominant negative form (dnLEF1), have been shown to have differential effects on the pathology of colorectal cancer, although higher levels of activation in the Wnt/β-catenin signaling pathway in general are correlated with increased cancer stem cell properties in murine tumors. These associations have far reaching implications in regards to the fields of cancer biology and medicine in general, as the enhanced sensitivity of cancer cells to chemotherapeutic agents upon inhibition of the LEF1 family and the corresponding TCF-1, TCF-2, TCF-3 and TCF-4 genes, allows for the development of more drugs that can target the inhibition of this specific pathway and lower the morbidity and mortality rates for a diverse range of cancerous pathologies.

Interactions

Lymphoid enhancer-binding factor 1 has been shown to interact with:

• ALX4,
• AML-1,
• Catenin beta-1/β-catenin/CTNNB1, including transgenically,
• EP300,
• MITF
• PIAS4,
• SMAD2, and
• SMAD3.
• ALX4, a protein encoded by the ALX4 gene found predominantly in the mesenchyme of developing embryonic limb buds. This protein is a potent transcriptional activator of the genes required during the development of the skeleton in the appendicular and craniofacial regions during embryonic development.
• AML-1, or acute-myeloid leukemia 1 protein, is a protein in humans encoded by the RUNX1 gene. It is also known as runt-related transcription factor 1 (RUNX1) and core-binding factor subunit alpha-2 (CBFA2), and plays an instrumental role in the development of pain-sensing neurons, as well as in the maturation of hematopoietic stem cells into mature blood cells. It was discovered by Nusslein-Volhard and Wieschaus during a screening of Drosophila in an attempt to elucidate specific mutations dealing with defects in the segmentation patterns and polarization of genes in Drosophila. Similar to the LEF1 interactions, AML-1 has been associated with mutational defects leading to a myriad of blood related pathologies. This list includes Familial Platelet Disorder, Acute myeloid leukemia, T-cell acute lymphoblastic leukemia (T-ALL), and multiple forms of myelodysplastic neoplasms.
• Catenin beta-1/β-catenin/CTNNB1, including transgenically, as this is a key component of the β-catenin and Wnt signaling pathway that the LEF1 protein plays a role in regulating. This role in transgenic expression has led to a number of studies done using modern genetic engineering techniques in order to determine the direct role of this Catenin beta-1/LEF1 association in the pathologies listed above. In fact, research has shown that LEF1 and β-catenin, when co-expressed in mammalian cells, combine with DNA in the nucleus to form a ternary complex. In turn, this activates the role of LEF1 as a transcription factor and demonstrates a mechanism by which signal transduction occurs from the Wnt proteins to the nucleus. This protein plays a role in both gene transcription of DNA to mRNA and cellular adhesion. As referenced earlier, β-catenin plays an integral role in the epithelial-to-mesenchymal transition, acting as a specific signaling molecule called a morphogen which helps guide development of cells in the later stages of embryonic development. Acting in tandem with LEF1, Catenin beta-1 causes certain epithelial cells to loosen their tight associations with the lumen and to adopt a looser and more fluid identity, similar to those seen by cells in the mesenchyme. This loosening of their associations causes the epithelial cells to inactive a number of proteins associated with adhesion and to activate a host of other proteins expressed in resident cells of the mesenchyme. These molecules include vimentin, alpha smooth muscle actin (ACTA2) and fibroblast-specific protein 1 (FSP1).
• EP300,
• MITF
• PIAS4,
• SMAD2, and
• SMAD3.

Further reading

• "Lymphoid enhancer factor/T cell factor expression in colorectal cancer". Cancer and Metastasis Reviews 23 (1–2): 41–52. 2004. doi:10.1023/A:1025858928620. PMID 15000148. 
• "LEF-1 is a decisive transcription factor in neutrophil granulopoiesis". Annals of the New York Academy of Sciences 1106 (1): 143–151. June 2007. doi:10.1196/annals.1392.012. PMID 17360796. Bibcode: 2007NYASA1106..143S. 
• "LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function [corrected]". Genes & Development 5 (5): 880–894. May 1991. doi:10.1101/gad.5.5.880. PMID 1827423. 
• "Identification and cloning of TCF-1, a T lymphocyte-specific transcription factor containing a sequence-specific HMG box". The EMBO Journal 10 (1): 123–132. January 1991. doi:10.1002/j.1460-2075.1991.tb07928.x. PMID 1989880. 
• "A thymus-specific member of the HMG protein family regulates the human T cell receptor C alpha enhancer". Genes & Development 5 (4): 656–669. April 1991. doi:10.1101/gad.5.4.656. PMID 2010090. 
• "Lymphoid enhancer factor 1 directs hair follicle patterning and epithelial cell fate". Genes & Development 9 (6): 700–713. March 1995. doi:10.1101/gad.9.6.700. PMID 7537238. 
• "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene 138 (1–2): 171–174. January 1994. doi:10.1016/0378-1119(94)90802-8. PMID 8125298. 
• "The nuclear localization signal of lymphoid enhancer factor-1 is recognized by two differentially expressed Srp1-nuclear localization sequence receptor proteins". The Journal of Biological Chemistry 271 (13): 7654–7658. March 1996. doi:10.1074/jbc.271.13.7654. PMID 8631802. 
• "Functional interaction of beta-catenin with the transcription factor LEF-1". Nature 382 (6592): 638–642. August 1996. doi:10.1038/382638a0. PMID 8757136. Bibcode: 1996Natur.382..638B. 
• "An HMG I/Y-containing repressor complex and supercoiled DNA topology are critical for long-range enhancer-dependent transcription in vitro". Genes & Development 11 (5): 629–639. March 1997. doi:10.1101/gad.11.5.629. PMID 9119227. 
• "ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for TCRalpha enhancer function". Genes & Development 11 (5): 640–653. March 1997. doi:10.1101/gad.11.5.640. PMID 9119228. 
• "A beta-catenin/XTcf-3 complex binds to the siamois promoter to regulate dorsal axis specification in Xenopus". Genes & Development 11 (18): 2359–2370. September 1997. doi:10.1101/gad.11.18.2359. PMID 9308964. 
• "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene 200 (1–2): 149–156. October 1997. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149. 
• "Two members of the Tcf family implicated in Wnt/beta-catenin signaling during embryogenesis in the mouse". Molecular and Cellular Biology 18 (3): 1248–1256. March 1998. doi:10.1128/MCB.18.3.1248. PMID 9488439. 
• "Differential importin-alpha recognition and nuclear transport by nuclear localization signals within the high-mobility-group DNA binding domains of lymphoid enhancer factor 1 and T-cell factor 1". Molecular and Cellular Biology 18 (8): 4819–4832. August 1998. doi:10.1128/MCB.18.8.4819. PMID 9671491. 
• "Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors". Proceedings of the National Academy of Sciences of the United States of America 95 (20): 11590–11595. September 1998. doi:10.1073/pnas.95.20.11590. PMID 9751710. Bibcode: 1998PNAS...9511590L. 
• "The human LEF-1 gene contains a promoter preferentially active in lymphocytes and encodes multiple isoforms derived from alternative splicing". Nucleic Acids Research 28 (9): 1994–2003. May 2000. doi:10.1093/nar/28.9.1994. PMID 10756202. 
• "Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways". Proceedings of the National Academy of Sciences of the United States of America 97 (15): 8358–8363. July 2000. doi:10.1073/pnas.150152697. PMID 10890911. Bibcode: 2000PNAS...97.8358L. 
• "All Tcf HMG box transcription factors interact with Groucho-related co-repressors". Nucleic Acids Research 29 (7): 1410–1419. April 2001. doi:10.1093/nar/29.7.1410. PMID 11266540. 

External links

• LEF1+protein,+human at the US National Library of Medicine Medical Subject Headings (MeSH)

This article incorporates text from the United States National Library of Medicine, which is in the public domain.